ABOS
Acumen Pharmaceuticals, Inc.·Healthcare
2.54
4.959%(+0.12)
Close PriceLast Updated: — ET
52W L: $1.0052W H: $3.60
Acumen Pharmaceuticals, Inc.·Healthcare
Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 2026 will be mostly about its upcoming Phase 2 readout. The main appeal still lies with sabirnetug, which could offer meaningful upside if Phase 2 data supports a viable path into Phase 3. As such, ALTITUDE-AD is the main swing factor, especially if iADRS slowing lands near management's target.
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals NASDAQ: ABOS said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer's disease pipeline.
NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2026 and provided a business update.
NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m.